-
Signature
-
/s/ Daniel Rodriguez as Attorney-in-Fact for Shriram Revankar
-
Issuer symbol
-
DLB
-
Transactions as of
-
21 Nov 2025
-
Net transactions value
-
-$196,650
-
Form type
-
4
-
Filing time
-
24 Nov 2025, 16:46:56 UTC
Reporting Owners (1)
| Name |
Relationship |
Address |
Signature |
Signature date |
CIK |
| Revankar Shriram |
SVP, Advanced Technology Group |
C/O DOLBY LABORATORIES, INC., 1275 MARKET STREET, SAN FRANCISCO |
/s/ Daniel Rodriguez as Attorney-in-Fact for Shriram Revankar |
24 Nov 2025 |
0001928994 |
Transactions Table
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
| transaction |
DLB |
Class A Common Stock |
Sale |
$196,650 |
-3,000 |
-4.3% |
$65.55 |
67,435 |
21 Nov 2025 |
Direct |
F1 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses: